Klisyri available for commercial use in Europe
Click Here to Manage Email Alerts
Klisyri is available for prescription in Germany and the U.K., according to a press release from Almirall.
Klisyri (tirbanibulin) is a novel topical microtubule inhibitor used in the treatment of actinic keratoses of the face and scalp in adults, which has increased in prevalence due to an aging population, increased exposure to UV radiation and changes in UV-seeking behaviors, the press release said.
“It's important to identify and treat [AK] lesions to help reduce the disease progression to skin cancer. In this context, the arrival of Klisyri to the market is an important addition to dermatologist’s armamentarium,” Gupta Girish, MB ChB, FRCP, said in the press release.
The U.S. rollout of Klisyri earlier this year followed approval from the FDA in December 2020, and was approved for commercialization in Europe by the European Commission and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in July 2021 and August 2021, respectively.